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Background: The next big challenge in human genetics is understanding the 98% of the genome that comprises
non-coding DNA. Hidden in this DNA are sequences critical for gene regulation, and new experimental strategies
are needed to understand the functional role of gene-regulation sequences in health and disease. In this study, we
build upon our HuGX (‘high-throughput human genes on the X chromosome’) strategy to expand our
understanding of human gene regulation in vivo.
Results: In all, ten human genes known to express in therapeutically important brain regions were chosen for
study. For eight of these genes, human bacterial artificial chromosome clones were identified, retrofitted with a
reporter, knocked single-copy into the Hprt locus in mouse embryonic stem cells, and mouse strains derived. Five
of these human genes expressed in mouse, and all expressed in the adult brain region for which they were chosen.
This defined the boundaries of the genomic DNA sufficient for brain expression, and refined our knowledge
regarding the complexity of gene regulation. We also characterized for the first time the expression of human
MAOA and NR2F2, two genes for which the mouse homologs have been extensively studied in the central nervous
system (CNS), and AMOTL1 and NOV, for which roles in CNS have been unclear.
Conclusions: We have demonstrated the use of the HuGX strategy to functionally delineate non-coding-regulatory
regions of therapeutically important human brain genes. Our results also show that a careful investigation, using
publicly available resources and bioinformatics, can lead to accurate predictions of gene expression.
Keywords: Humanized mouse models, Brain expression pattern, Eye expression pattern, Brain development,
Reporter gene, Transgenic mice, Hprt locus, High-throughput, Bacterial artificial chromosomeBackground
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reproduction in any medium, provided the orhuman diseases and disorders. The study of protein-
coding DNA sequences remains important, but also fo-
cuses on only a small fraction of the human genome
(2%). The next big challenge in the field of human genet-
ics lies in understanding the role of the remaining 98%
of the genome, which comprises non-coding DNA se-
quences critical for gene regulation, chromosome func-
tion, and generation of untranslated RNAs [1]. New
experimental strategies are needed to understand the
functional role of non-coding sequences in health and
disease. Pioneer examples in this work include large-
scale efforts from the Encyclopedia of DNA Elementstral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elements in the human genome, and the Pleiades Pro-
moter Project [3] identifying brain-specific regulatory ele-
ments using humanized mouse models [4,5]. The latter
project aimed at refining our understanding of regulatory
elements, as well as providing researchers with novel tools
for directed gene expression in restricted brain regions [5].
These tools were designed to be amenable to gene therapy
as they were MiniPromoters of less than 4 kb, made en-
tirely from human DNA elements, and selected for ex-
pression in 30 brain regions and cell types of therapeutic
interest [5,6]. However, the bioinformatic approaches used
for MiniPromoter design resulted in a biased selection for
genes with low regulatory complexity, having well-defined
and conserved non-coding regions that were close to the
transcription start site (TSS) [5].
An additional set of ten genes, which were judged to
be important for brain expression and/or relevance to
disease, were omitted from Pleiades MiniPromoter de-
velopment because they either had regulatory regions
that were too large, too numerous candidate regulatory
regions, or multiple TSS. For these genes, the Pleiades
Promoter Project designed MaxiPromoters as an alterna-
tive [6]. A MaxiPromoter consists of a bacterial artificial
chromosome (BAC) that has a reporter gene sequence
(lacZ or EGFP) inserted at the start codon. For a BAC to
be ideally suited for MaxiPromoter design, it has to span
the whole predicted gene sequence plus extensive flank-
ing intergenic sequences, but cannot contain the pre-
dicted promoter region of an adjoining gene.
These MaxiPromoters were used to test the veracity
of the predicted regulatory regions, as well as to define
the boundaries of the genomic DNA that were sufficient
for brain-specific expression, thus leading to a refine-
ment of our knowledge regarding the complexity of
gene regulation. The strategy used to generate the mice
for expression study in vivo was built on our method for
high-throughput single-copy site-specific generation of
humanized mouse models; entitled HuGX (‘high-through-
put human genes on the X chromosome’) [7]. Charac-
terization of expression from the MaxiPromoter reporter
construct was performed in development at embryonic
day 12.5 (E12.5), postnatal day 7 (P7), and adult brain and
eyes. In this study, we characterize for the first time the
expression of human MAOA, and NR2F2, two genes for
which the mouse homologs have been extensively studied
in central nervous system (CNS) development [8-14], and
AMOTL1 and NOV, for which roles in CNS have been un-
clear in either species.
AMOTL1 (angiomotin-like 1), initially known as
junction-enriched and -associated protein (JEAP), en-
codes a member of the motin protein family [15,16]. The
gene was selected for being enriched for expression in
the thalamus, a brain region implicated in the cognitiveimpairment of early stage Huntington’s disease (HD) [17].
In vitro and in vivo mouse studies have demonstrated that
the Amotl1 protein localizes at ‘tight’ junctions in cells
[15]. Amotl1 regulates sprouting angiogenesis by affecting
tip cell migration, and cell-cell adhesion in vivo [18].
Northern blot analysis demonstrated high levels of tran-
scripts of the mouse Amotl1 gene in the brain, heart,
lung, skeletal muscle, kidney, and uterus [16]. These
results differed from previously reported immunohisto-
chemical analysis demonstrating absence of expression in
the brain, heart, and kidney [15]. Discrepancy between the
studies can be partly explained by the existence of differ-
ent isoforms of the Amotl1 protein, highlighting the need
for further characterization [18].
MAOA (monoamine oxidase A) is a gene encoding a
membrane-bound mitochondrial flavoprotein that deami-
nates monoaminergic neurotransmitters [11,19]. The gene
was selected for expression in the locus coeruleus (LC), a
component of the neuroadrenergic system that has been
linked to the etiology of depressive illness [20]. In mice,
characterization of Maoa by in situ hybridization and im-
munohistochemistry during CNS development dem-
onstrated expression in a variety of neurons, including
noradrenergic and adrenergic neurons as well as dopamin-
ergic cells in the substantia nigra [21]. Maoa is expressed
in neurons populating the developing brainstem, amyg-
dala, cranial sensory ganglia, and the raphe [21]. Transient
expression in cholinergic motor nuclei in the hindbrain,
and in non-aminergic neurons populating the thalamus,
hippocampus, and claustrum has also been detected dur-
ing development [21]. In adult rodent brain, Maoa tran-
scription is detected in neurons populating the cerebral
cortices, the hippocampal formation (HPF), and the cere-
bellar granule cell layer [22]. Maoa knockout models
implicate this gene as a regulator of neurochemical
pathways, leading to increased levels of serotonin (5-
hydroxytryptamine (5-HT)), norepinephrine, dopamine,
and noradrenaline neurotransmitters in adult brain
[23,24]. This increased level of neurotransmitters leads
to behavioral abnormalities including aggression, which
can be rescued by a Maoa forebrain-specific transgenic
mouse model [23-26]. The role of Maoa in regulating
neurotransmitters also impacts development by affect-
ing telencephalic neural progenitors and retinal gan-
glion cell projections [12,14].
NOV (nephroblastoma overexpressed gene), belongs to
the CCN (CYR61, CTGF and NOV) family of secreted
matrix-associated signaling regulators [27]. The gene was
selected for being enriched in the amygdala and basolat-
eral complex, which includes brain regions that have been
implicated in affective processing and memory [28]. The
NOV protein stimulates fibroblast proliferation via a tyro-
sine phosphorylation dependent pathway [29]. In mice,
Nov characterization by in situ hybridization revealed that
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dermomyotomal cells of muscular origin along the entire
embryonic rostrocaudal axis [27]. In the CNS, Nov tran-
scripts are first detected at E11.5 in scattered cells of the
olfactory epithelium, the developing cochlea and the tri-
geminal ganglia [27]. Transcription observed in the olfac-
tory epithelium extends later to cells populating the
olfactory lobe (E13.5) [27]. At E12.5 and onward, Nov
transcription is detected in muscle cell types of diverse de-
veloping tissues including vertebral muscles, limb muscles
(femur, and hind foot), aorta, and other major vessels,
maxillary muscles, and extraocular muscles [27]. Add-
itionally, at E12.5, Nov transcription is observed in devel-
oping motor neurons in the ventral horns of the spinal
cords [27]. In situ hybridization transcript localization on
human fetal tissues revealed similar results and suggest
that NOV plays an important role in neuronal differenti-
ation [30]. Furthermore, investigation on prenatal lead ex-
posure has revealed a reduction in the expression level of
Nov in rat offspring hippocampus, demonstrating a poten-
tial mechanism by which lead exposure affects learning
and memory [31]. Overall, these results highlight the need
for further investigation of the role of NOV in central ner-
vous system.
NR2F2 (nuclear receptor 2f2), also known as COUP-
TFII/ARP1, is a gene encoding for a transcription factor
belonging to the orphan receptors group. Like NOV,
NR2F2 was selected for being enriched in the amygdala
and basolateral complex, which includes brain regions
that have been implicated in affective processing and
memory [28]. In mice, transcription of Nr2f2 by in situ
hybridization during CNS development is first observed
at embryonic day 8.5 (E8.5), peaks at E14 to 15, and de-
clines after birth [9]. Nr2f2 expression in the developing
telencephalon is restricted to the caudal lateral domains,Table 1 Eight out of ten constructs successfully modified for
Brain region(s) Gene Plea Parental BAC name
Thalamus AMOTL1 5 RP11-936P10
Brainstem, pons, medulla GLRA1 91 RP11-602K10
Hippocampus, dentate gyrus LCT 126 RP11-406M16
Locus coeruleus MAOA 127 RP11-475M12
Hippocampus, Ammon’s horn NEUROD6 132 RP11-463M14
Basal nucleus of Meynert NGFR 133 RP11-158L10
Amygdala, basolateral complex NOV 134 RP11-840I14
Neurogenic regions NR2E1 142 RP11-144P8
Amygdala, basolateral complex NR2F2 143 RP11-134D15
Subthalamic nucleus PITX2 158 RP11-268I1
aPleiades (Ple) promoter design number.
bGLRA1 failed retrofitting with Hprt homology arms.
cNEUROD6 failed BAC isolation from the library.
BAC bacterial artificial chromosome, N/A not applicable.with positive staining in the medial ganglionic eminence,
and caudal ganglionic eminence (CGE) [9,10]. Nr2f2
function in the CGE is essential for the migration of in-
hibitory interneurons during forebrain development [10].
These interneurons migrate from the CGE via the caudal
migratory stream to populate the neocortex, hippocam-
pus, and amygdala [32,33]. Recent studies demonstrated a
role for Nr2f2, and its closest relative (Nr2f1) in regulating
the temporal specification of neural stem/progenitor cells
in the ventricular zone of the developing CNS [13]. In the
adult CNS, Nr2f2 is expressed in a subpopulation of
calretinin-positive interneurons in the postnatal cortex,
and a population of amacrine cells in the mouse adult ret-
ina [8,10]. Finally, Nr2f2 participates in the development
and proper function of multiple organs, including the
inner ear, limbs, skeletal muscles, heart, and pancreas
[34-37]. The expression of Nr2f2 in heart and pancreatic
development highlights the role of this gene in regulating
angiogenesis, a property that in turn affects tumor growth,
and metastasis in cancer [38].
Results and discussion
High-throughput construction of humanized mice to
study gene expression
Gene choosing for this study was based in part on serial
analysis of gene expression (SAGE) profiling of brain re-
gions of therapeutic interest, as well as data mining of both
the Allen Mouse Brain Atlas (ABA) [39] and Brain Gene
Expression Map (BGEM) [6,40-42]. The ten chosen human
genes all had enriched expression of their mouse homologs
in brain regions of therapeutic interest (Table 1). The ex-
pression pattern of these human genes was then analyzed
in this study using mouse models generated through the
HuGX method, that is, carrying a single copy of a human
BAC MaxiPromoter reporter construct docked at the Hprtexpression-pattern characterization in mice
Construct size (bp) Reporter BAC name Retrofitting status
211,681 lacZ bEMS90 Successful
188,541 N/A bEMS89 Failedb
156,570 EGFP bEMS75 Successful
197,191 lacZ bEMS84 Successful
N/A N/A N/A Failedc
175,851 lacZ bEMS88 Successful
202,342 lacZ bEMS91 Successful
138,165 lacZ bEMS86 Successful
213,112 lacZ bEMS85 Successful
200,209 lacZ bEMS87 Successful
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DNA boundaries that were predicted to be sufficient for
adult brain-specific expression of the selected human
genes, and to document the expression pattern resulting
from the human MaxiPromoter constructs at different de-
velopmental stages in mouse.
Of the ten selected genes, eight BAC MaxiPromoters
were successfully constructed that contained an Hprt
complementation cassette and a reporter gene (lacZ or
EGFP) (Table 1). One planned BAC construct, RP11-463
M14 (NEUROD6), was abandoned due to rearrangement
in the parental BAC clone, resulting in a smaller DNA in-
sert than expected. Thus, using our retrofitting approach a
success rate of 89% (8 out of 9) was obtained, with the lar-
gest construct spanning >213 kb (Table 1). The only retro-
fitting failure was partly due to an irresolvable primer
design issue for GLRA1 (Table 1). While many technical
challenges can occur when using recombineering technol-
ogy in a high-throughput manner, the high success rate
obtained in our approach demonstrates the overall effi-
ciency of the technology.
The eight retrofitted MaxiPromoter constructs were
electroporated into embryonic stem cells (ESCs), and
positive recombinant clones were selected, and screened
as described in materials and methods. On average, 35%
(range 20 to 53) correctly targeted clones were recovered
for each construct (Table 2). For each MaxiPromoter,
correctly targeted ESCs were microinjected to generate
chimeric animals from which germline transmission was
obtained; 100% success rate (8/8). MaxiPromoter expres-
sion was evaluated in E12.5 embryos, P7 brains, and
adult brains and eyes. Gross dissection and whole body
staining for expression investigation of adults was also
performed. Based on these studies, 63% (5/8) MaxiPro-
moter strains were positive for expression of the human
gene in mouse tissues (Table 3). Of the three negative
strains, the failure to detect expression from the LCTTable 2 Eight novel Hprt targeted embryonic stem cell lines s
Gene Parental ESC
Line (mEMS) Genotype of parental ESC line
AMOTL1 1202.04 B6129F1-Gt(ROSA)26Sor+/+, Hprtb-m3/Y
LCT 1204.31 B6129F1-Gt(ROSA)26Sortm1Sor/+, Hprtb-m3/Y
MAOA 1202.04 B6129F1-Gt(ROSA)26Sor+/+, Hprtb-m3/Y
NGFR 1202.04 B6129F1-Gt(ROSA)26Sor+/+, Hprtb-m3/Y
NOV 1202.04 B6129F1-Gt(ROSA)26Sor+/+, Hprtb-m3/Y
NR2E1 1204 B6129F1-Gt(ROSA)26Sortm1Sor/+, Hprtb-m3/Y
NR2F2 1292.02 B6129F1-Aw-J/Aw, Gt(ROSA)26Sortm1Sor/+, Hprtb-m
PITX2 1202.04 B6129F1-Gt(ROSA)26Sor+/+, Hprtb-m3/Y
aObtained from multiple electroporations.
ESC embryonic stem cell.
mEMS (mammalian cell lines Elizabeth M. Simpson).MaxiPromoter could be attributable to sensitivity issues
regarding the EGFP reporter gene. This fluorescence re-
porter was subsequently excluded from our single-copy
insertion work [5], and replaced with the lacZ reporter,
which offers greater sensitivity when direct readout of
the enzymatic product is used. All other MaxiPromoter
constructs were retrofitted with lacZ. The two additional
negative results, for the NGFR and PITX2 strains, could
be attributable to undetected construct mutations. How-
ever, almost all the deletions that were detected, during
screening for correctly targeted ESC clones (Table 2),
were large and eliminated multiple polymerase chain re-
action (PCR) assays. Furthermore, both the NGFR and
PITX2 strains were examined using the same multiple
PCR assays, which showed that the BAC constructs had
not changed in the mice. Hence, these negative results
were more likely due to missing human gene regulatory
regions, and/or the human regulatory regions present in
the BAC being non-functional in the mouse genome. In
parallel to our work, the Gene Expression Nervous System
Atlas (GENSAT) project [43] reported positive brain ex-
pression using mouse Pitx2 and Ngfr in random-insertion
BAC-mouse models (Pitx2, RP24-215O15; Ngfr, RP23-
138M22) [44]. Sequence comparison, using relative coordi-
nates between human and mouse, revealed that our human
BAC constructs (PITX2, RP11-268I1; NGFR, RP11-158
L10) were shorter than the mouse BACs used by GENSAT.
PITX2 was shorter at the 5′ end by approximately 30 kb,
and NGFR was shorter at the 3′ end by approximately
40 kb. Thus, our work suggests a testable hypothesis that
important regulatory elements reside in these differential
regions. Finally, we characterized in detail the expression
patterns observed from four of the five positive humanized
mouse strains generated in this project: AMOTL1-lacZ,
MAOA-lacZ, NOV-lacZ and NR2F2-lacZ. The detailed
analysis of the NR2E1-lacZ strain was presented in a previ-
ous publication [45].uccessfully generated
ESC clones Final ESC
line (mEMS)Number isolated Correctly targeted (%)
8 50 4645
31 48 3305
15 53 4442
20 20 4583
24 42 4521
29a 21 4751
3/Y 25a 28 4990
15 20 4496
Table 3 Summary of expression pattern from reporter mouse strains
Gene Embryo E12.5 P7 brain Adult brain Eye Other MMRRC strain name MMRRC stock no.
AMOTL1 Positive Positive Positive Positive Positive B6.129P2(Cg)-Hprttm66(Ple5-lacZ)Ems/Mmjax 012354
LCT Negative Negative Negative N/D N/D N/A N/A
MAOA Positive Positive Positive Positive Positive B6.129P2(Cg)-Hprttm68(Ple127-lacZ)Ems/Mmjax 012583
NGFR Negative Negative Negative Negative Negative N/A N/A
NOV Positive Positive Positive Negative Positive B6.129P2(Cg)-Hprttm69(Ple134-lacZ)Ems/Mmjax 012584
NR2E1 Positive Positive Positive Positive N/D B6.129P2(Cg)-Hprttm73(Ple142-lacZ)Ems/Mmjax 032962
NR2F2 Positive Positive Positive Negative Positive B6.129P2(Cg)-Hprttm75(Ple143-lacZ)Ems/Mmjax 014536
PITX2 Negative Negative Negative Negative Negative N/A N/A
MMRRC Mutant Mouse Regional Resource Center, N/A not applicable, N/D not determined.
Schmouth et al. BMC Biology 2013, 11:106 Page 5 of 21
http://www.biomedcentral.com/1741-7007/11/106Human genes can be conditionally deleted using flanking
functional loxP sites
The HuGX method used in this study consisted of retrofit-
ting existing human BAC constructs to carry an Hprt
complementation cassette that allowed site specific target-
ing into the genome of Hprtb-m3 ESCs by homologous re-
combination [7]. The resulting complementation targeting
event was detectable using described PCR assays [46]. The
insertion of the Hprt complementation cassette by recom-
bineering resulted in the disruption of a SacB gene present
on the original BAC vector, as well as the addition of loxP
sites flanking the entire human gene. To verify that these
loxP sites were functional in the final MaxiPromoter carry-
ing strains, we bred AMOTL1-lacZ, MAOA-lacZ, NOV-
lacZ and NR2F2-lacZ female mice to ACTB-cre male
mice (Figure 1a,b), and examined the resulting brain ex-
pression patterns from male offspring. Positive animals for
the complementation at the Hprt locus by genotyping
were evaluated based on the presence or absence of the
ACTB-cre transgene. The results showed that in all
strains, lacZ staining (blue) was only detected in males,
positive for the complementation at the Hprt locus and
negative for the presence of the ACTB-cre transgene
(AMOTL1-lacZ, MAOA-lacZ, NOV-lacZ, and NR2F2-
lacZ) (first panel of Figure 1c-f). Absence of lacZ staining
was only found in brains of the animals that were positive
for both the complementation at the Hprt locus and the
ACTB-cre transgene (AMOTL1-lacZ, ACTB-cre; MAOA-
lacZ, ACTB-cre; NOV-lacZ, ACTB-cre; NR2F2-lacZ,
ACTB-cre), suggesting complete excision of the BAC con-
struct from the genome and proper function of the loxP
sites (second panel of Figure 1c-f).
Human AMOTL1-lacZ revealed staining in mature thalamic
neurons in adult brain, and amacrine as well as ganglion
cells in adult retina
AMOTL1 expression was predicted to be in the thal-
amus in the adult brain. Whole mount lacZ E12.5
stained embryos revealed expression of the AMOTL1 re-
porter construct in components of the vascular system
such as the jugular vein, the posterior cerebral artery,and the vertebrate arteries (Figure 2a). Additional ana-
lyses using embryos subjected to a clearing protocol
confirmed staining in the previously described regions,
and revealed expression in the basilary artery, the dorsal
aorta, and vertebrate arteries (Figure 2b). Staining was
observed in the omphalomesenteric vascular system, and
the lateral nasal prominence (Figure 2b). P7 developing
mouse brain sections revealed expression in the anterior
thalamic nuclei, and HPF (Figure 2c). Adult mouse brain
sections revealed expression in the anteromedial, and
anteroventral thalamic nuclei, the pontine nuclei, and
the HPF, with sharp staining in the cornu ammonis
fields (CA1 and CA3) (Figure 2d,e). Additional staining
was detected in the subiculum and extended to the
lower cortical layers with pronounced staining in layer
VI (Figure 2e). On cryosections positive colocalization
between the β-gal staining product (blue) and neuronal
nuclei (NeuN)-specific antibody (brown) indicated that
the AMOTL1 reporter construct was expressed in ma-
ture neurons in all brain regions, including the antero-
ventral thalamic nuclei (Figure 2f ). The β-gal-positive
cells (blue) did not colocalize with glial fibrillary acidic
protein (GFAP) (brown), a marker of astrocytes (data
not shown). Further AMOTL1-lacZ expression pattern
characterization revealed staining in the adult retina,
extending from the inner limiting membrane (ILM)
to the junction between the inner plexiform layer
(IPL) and the inner nuclear layer (INL) (Figure 2g).
The β-gal staining product (blue) detected at the
junction of the IPL, and INL, colocalized with anti-
tyrosine hydroxylase (anti-TH) (brown), demonstrat-
ing expression of the AMOTL1 MaxiPromoter re-
porter construct in a subpopulation of amacrine cells
found in the INL (Figure 2h) [47]. Colocalization
using an anti-Brn3 antibody revealed expression in
the ILM corresponding to ganglion cells in the retina
(Figure 2i). Additional staining was found in the
nasal structures, extending from the naris, to the
nasopharynx, and at the sternum junction, in the ex-
tremities of the ribs in the AMOTL1-lacZ animals in
gross dissections (data not shown).
Figure 1 Human bacterial artificial chromosomes can be targeted at Hprt by homologous recombination and, if desired, conditionally
removed using cre recombinase. (a) Integration into the mouse genome of the bacterial artificial chromosome (BAC)-lacZ-reporter constructs by
homologous recombination results in the human gene in either direction relative to the X chromosome; this schematic presents one possible orientation.
Regardless of orientation, each insertion resulted in the presence of four loxP sites in the genome (two wild-type and one 511 mutant at one end and one
wild-type at the other end of the BAC insert). (b) Crossing the BAC-lacZ-reporter females to ACTB-cre males should result in the generation of two different
male offspring; BAC-lacZ-reporter animals, wild-type for the ACTB-cre transgene; and BAC-lacZ-reporter animals carrying the ACTB-cre transgene. Only the
reporter animals that are positive for the ACTB-cre gene should recombine the outer most loxP sites, resulting in excision of the BAC construct from the
genome and leaving one loxP site. This would result in an absence of lacZ-positive signal. hP, human HPRT promoter; h1, human first exon; m2 and m3,
mouse second and third exons; mouse homology arms (dark blue); Hprt coding regions (red); vector backbone (yellow with black edges); SacB gene from
BAC vector backbone (brown); 5′ and 3′ untranslated regions of the human gene (orange); coding region of the human gene (green); lacZ reporter gene
(light blue). Schematic, not to scale. (c-f) lacZ expression results from AMOTL1-lacZ, MAOA-lacZ, NOV-lacZ, and NR2F2-lacZ females bred to the ACTB-cre
males are presented. lacZ-positive staining (blue) was detected in AMOTL1-lacZ, MAOA-lacZ, NOV-lacZ, and NR2F2-lacZ males not carrying the ACTB-cre
allele whereas absence of staining was detected in males positive for ACTB-cre by genotyping (AMOTL1-lacZ, ACTB-cre; MAOA-lacZ, ACTB-cre; NOV-lacZ,
ACTB-cre; NR2F2-lacZ, ACTB-cre), suggesting whole BAC excision from the genome. Scale bar: (c-f) 1 mm. N = 3 animals for all genotypes.
Schmouth et al. BMC Biology 2013, 11:106 Page 6 of 21
http://www.biomedcentral.com/1741-7007/11/106Human MAOA-lacZ revealed staining in TH-positive
neurons in the locus coeruleus in adult brain as well as
horizontal, and ganglion cells in adult retina
MAOA expression was predicted to be observed in the
LC in the adult brain. Whole mount lacZ E12.5 stainedembryos revealed expression in the prepontine hindbrain
that extended to the basal midbrain and the prosomeres 1
and 2 of the diencephalon (Figure 3a). Staining extended
from the pontine hindbrain (pons proper) to the medullary
hindbrain (medulla) (Figure 3a). E12.5 cleared embryos
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revealed expression of the MAOA reporter construct in
major neuron fibers extending from the prepontine hind-
brain, and the pontine hindbrain (Figure 3b). Staining was
present in fibers of the medullary hindbrain that extended
into the thoracic cavity; and fibers of the ventral region of
the somites that started in the upper thoracic cavity, and
extended towards the posterior limbs (Figure 3b). P7Figure 2 (See legend on next page.)developing mouse brain sections revealed expression at the
lateral extremities of the fourth ventricle, demonstrating
expression of theMAOA MaxiPromoter reporter construct
in the region of the LC at this developmental stage
(Figure 3c). Adult mouse-brain-section staining revealed
high levels of expression in the LC and lateral cerebellar
nuclei, as well as the medial and lateral vestibular nuclei
(Figure 3d). Further colocalization experiments on
(See figure on previous page.)
Figure 2 Human AMOTL1-lacZ expressed in mature neurons in the thalamus in adult brain, amacrine and ganglion cells in adult retina, and
major components of the vasculature system during development. Expression analysis of the human AMOTL1-lacZ strain was examined using β-
galactosidase (β-gal) histochemistry staining (blue). (a) E12.5 whole embryos stained in the jugular vein (black arrow), posterior cerebral artery (white arrow),
and vertebral arteries (black arrowhead). (b) E12.5 cleared embryos additionally demonstrated staining in the basilary artery (black arrow), the dorsal aorta
(white arrow), the omphalomesenteric vascular system (white arrowhead), and the lateral nasal prominence (black arrowhead). (c) P7 brains stained in the
developing anterior thalamic nuclei (black arrows), and hippocampal formation (HPF) (white arrows). (d) Adult brains stained in the anteromedial and
anteroventral thalamic nuclei (black arrow), and the pontine nuclei (white arrow). (e) The HPF showed sharp staining in the cornu ammonis fields (CA1,
and CA3). Staining was also present in the dorsal subiculum and extended to the lower cortical layers with pronounce staining in layer VI. (f) Colocalization
experiment using β-gal staining and neuronal nuclei (NeuN) immunohistochemistry (brown) performed on adult brain cryosections demonstrated
expression of AMOTL1-lacZ in thalamic neurons. (g) Staining was detected in two layers of the adult retina, the inner limiting membrane (ILM) (black
arrows), and the junction between the inner plexiform layer (IPL) and the ILM. (h) Colocalization experiment using β-gal staining and an anti-tyrosine
hydroxylase (anti-TH) antibody (brown) performed on adult eye cryosections indicated colocalization of AMOTL1-lacZ in amacrine cells populating the inner
nuclear layer (INL) (black arrows). (i) Colocalization experiment using β-gal staining and an anti-Brn3 antibody (brown) performed on adult eye cryosections
indicated colocalization of AMOTL1-lacZ in ganglion cells populating the ganglion cell layer (GCL) (black arrows). AV, anteroventral thalamic nucleus; ctx,
cortex; Hip, hippocampus; ONL, outer nuclear layer; SUB, subiculum. Scale bar: (a-d) 1 mm; (e) 500 μm; (f) 100 μm; (g-i) 20 μm.
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(blue) was expressed in mature neurons, positive for NeuN
(brown), in all brain regions, including the LC and medial
parabrachial nucleus (Figure 3e; higher magnification on
the LC, Figure 3f). The β-gal staining product (blue) found
in the LC colocalized with TH-positive cells (brown),
revealing expression of the MAOA reporter construct in
TH-positive neurons populating the LC (Figure 3g,h). The
β-gal-positive cells (blue) in the LC did not colocalize with
GFAP (brown), a marker of astrocytes (data not shown).
Furthermore, MAOA-lacZ expression pattern charac-
terization revealed staining in several layers in the adult
retina such as the ILM, the outer plexiform layer (OPL),
and the outer limiting membrane (Figure 3i). Calbindin is
a marker for three different cell types in the retina: the
ganglion cells that populate the ganglion cell layer (GCL),
the amacrine cells found in the INL, and the horizontal
cells populating the OPL [47]. Colocalization using an
anti-Calbindin antibody revealed that the MAOA-lacZ
construct was expressed in both the horizontal cells popu-
lating the OPL and the ganglion cells found in the GCL
(Figure 3j,k). Additional staining was detected along the
spinal cord in the MAOA-lacZ animals in gross dissec-
tions (data not shown).
Human NOV-lacZ revealed staining in neurons populating
the hippocampal formation, basolateral amygdaloid
nuclei, and cortical layers in adult brain
NOV expression was predicted to be observed in the
amygdala and basolateral complex in the adult brain
using our approach. Whole mount lacZ E12.5 stained
and cleared embryos revealed expression throughout
the olfactory epithelium and the primitive nasopharynx
(Figure 4a,b). P7 developing mouse brain sections demon-
strated strong expression of the NOV MaxiPromoter re-
porter construct in the retromammillary nucleus (RM) and
light expression in the HPF (Figure 4c). Adult mouse brain
sections had high expression levels in the mid-cortical
layers, and the HPF (Figure 4d). Pronounced staining wasdetected in the posterior basolateral amygdaloid nuclei
(BLP), and the adult RM (Figure 4d,e). We investigated the
nature of the positive cells expressed in the upper cortical
layers, HPF, and BLP using colocalization experiments on
cryosections. Positive colocalization between the β-gal
staining product (blue) and NeuN (brown) revealed that
the NOV reporter construct was expressed in mature neu-
rons in all brain regions, including the cortical layers II, IV
and VI, as well as the HPF, and BLP (Figure 4f-h). The
staining pattern in the HPF suggested expression in pyram-
idal neurons, with staining of the cell body in the CA1 that
extended into the apical dendrites found in the stratum
radiatum (Figure 4g). A similar experiment, using GFAP as
a marker of astrocytes, revealed absence of colocalization
of the NOV-lacZ reporter construct in astrocytes populat-
ing the cortex, HPF, and BLP (data not shown).
Human NR2F2-lacZ revealed staining in mature neurons,
immunoreactive for the Nr2f2 mouse protein in the
basolateral, and corticolateral amygdaloid nuclei in adult
brain
NR2F2 expression was predicted to be in the amygdala and
basolateral complex in the adult brain. Whole mount lacZ
E12.5 stained embryos revealed strong expression of the
NR2F2 MaxiPromoter construct in the rostral secondary
prosencephalon that extended throughout all three proso-
meric regions of the diencephalon (Figure 5a). Staining was
present in the nasal cavity, the vestibulochochlear ganglion,
and mesenchyme of the posterior limbs (Figure 5a). E12.5
cleared embryos confirmed staining in the previously
described regions, and suggested expression of the NR2F2
human gene in the developing bladder (Figure 5b). P7 de-
veloping mouse brains sections revealed expression of the
NR2F2 reporter construct in the amygdala and subthalamic
nuclei (Figure 5c). Adult mouse brain sections exhibited ex-
pression in brain regions including the posterior BLP, the
basomedial amygdaloid nuclei (BMP), the posterolateral
cortical amygdaloid nuclei (PLCo), the posteromedian cor-
tical amygdaloid nuclei (PMCo), and the posteroventral
Figure 3 Human MAOA-lacZ expressed in tyrosine hydroxylase (TH)-positive neurons in the locus coeruleus in adult brain, horizontal
and ganglion cells in the adult retina, and several regions of the developing hindbrain. Expression analysis of the human MAOA-lacZ strain
was examined using β-galactosidase (β-gal) histochemistry (blue). (a) E12.5 whole embryos stained in the prepontine hindbrain (black arrow) that
extended to the basal midbrain and the prosomeres 1 and 2 of the diencephalon (white arrows). Staining extended from the pontine hindbrain
(pons proper) to the medullary hindbrain (medulla) (white arrowhead). Staining was notable in the anterior part of the developing limbs (black
arrowhead). (b) E12.5 cleared embryos additionally demonstrated staining in fibers of the prepontine hindbrain, and the pontine hindbrain.
Staining was present in fibers of the medullary hindbrain that extended into the thoracic cavity; and fibers of the ventral region of the somites
that started in the upper thoracic cavity, and extended towards the posterior limbs. (c) P7 brains showed staining in nuclei surrounding the
fourth ventricle, a region where the locus coeruleus (LC) is located (black arrows). (d) Adult brains stained in the LC (black arrows), and lateral
cerebellar nuclei (white arrows). Staining was also present in the medial vestibular nuclei, and lateral vestibular nuclei. (e) Colocalization
experiment using β-gal staining and neuronal nuclei (NeuN) immunohistochemistry (brown) performed on adult brain cryosections suggested
expression of MAOA-lacZ in mature neurons in the LC. Sparse staining was detected in neurons populating the medial parabrachial nucleus.
Boxed region in (e) is shown in (f). (f) Higher magnification revealed expression of β-gal in neurons in the LC (black arrows). (g) Colocalization
experiment using β-gal staining and an anti-TH immunohistochemistry (brown) performed on adult brain cryosections suggested expression of
MAOA-lacZ in TH-positive neurons populating the LC. Boxed region in (g) is shown in (h). (h) Higher magnification revealed expression of β-gal
in TH-positive neurons in the LC (black arrows). (i) Staining was detected in the retina, extending from the inner limiting membrane (black
arrows) to the outer plexiform layer (white arrows), and the outer limiting membrane (OLM). (j,k) Colocalization experiment using β-gal staining
and an anti-calbindin (anti-Calb) immunohistochemistry (brown) performed on adult eye cryosections suggested expression of MAOA-lacZ in
horizontal cells populating the OPL (white arrows), and ganglion cells populating the ganglion cell layer (black arrows). Boxed region in (j) is
shown magnified in (k). INL, inner nuclear layer; IPL, inner plexiform layer; MBP, medial parabrachial nucleus; ONL, outer nuclear layer; V4, fourth
ventricle. Scale bar: (a-d) 1 mm; (e,g) 100 μm; (f,h) 25 μm; (i-k) 20 μm.
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Figure 4 Human NOV-lacZ expressed in the basolateral amygdaloid nuclei, mid-cortical layers, and pyramidal neurons of the
hippocampal formation. Expression analysis of the human NOV-lacZ strain was undertaken by examination of β-galactosidase (β-gal) staining
(blue). (a,b) E12.5 whole and cleared embryos showed staining in the olfactory epithelium, and the primitive nasopharynx (black arrows). (c) P7
brains stained in the developing retromammillary nucleus (RM) (black arrows), and hippocampal formation (HPF) (white arrows). (d) Adult brains
stained in the mid-cortical layers (black arrows), and the HPF (white asterisks). Staining was detected in the basolateral amygdaloid nuclei (BLP)
(white arrows). (e) NOV-lacZ staining was also present in the adult RM (white arrows). (f) Colocalization experiment using β-gal staining and a
neuronal nuclei (NeuN) antibody (brown) performed on adult brain cryosections revealed expression of NOV-lacZ in mature neurons in the
cortical layers II, IV and VI. (g) Colocalization experiment revealed expression of NOV-lacZ in pyramidal neurons populating the HPF (NeuN,
brown). Staining was found in the cell body in the cornu ammonis 1 region (CA1) (black arrow) and extended in the projections found in the
stratum radiatum (SR). (h) Colocalization experiment revealed expression of NOV-lacZ in mature neurons (NeuN, brown) found in the BLP. Ctx,
cortex. Scale bar: (a-e) 1 mm; (f,g) 50 μm; (h) 25 μm.
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Figure 5 Human NR2F2-lacZ expressed in mature neurons populating the basolateral and corticolateral amygdaloid nuclei that are
immunoreactive for the Nr2f2 mouse protein. Expression analysis of the human NR2F2-lacZ strain was undertaken by examination of
β-galactosidase (β-gal) staining (blue). (a) E12.5 whole embryos revealed staining in the rostral secondary prosencephalon (black arrow) that
extended throughout all three prosomeric regions of the diencephalon (black arrowhead). Staining was present in the nasal cavity (white arrow),
the vestibulochochlear ganglion (red arrowhead) and mesenchyme of the posterior limbs (white arrowhead). (b) E12.5 cleared embryos
additionally demonstrated staining in the developing bladder (black arrow). (c) P7 brains stained in the amygdala nuclei (white arrows), and the
subthalamic nuclei (black arrows). (d) Adult brains revealed strong staining extending from the posterior basolateral amygdaloid nuclei (BLP)
(black arrows) to the posterolateral cortical amygdaloid nuclei (PLCo) (white arrows), and the posteroventral part of the medial amygdaloid nuclei
(MePV) (white arrowheads). Broad staining was detected in the ventral thalamic area, excluding the cerebral peduncle (cp). (e) Colocalization
experiment using β-gal staining and a neuronal nuclei (NeuN) antibody (brown) performed on adult brain cryosections revealed strong
expression of NR2F2-lacZ in mature neurons populating the BLP, and the basomedial amygdaloid nuclei (BMP) (red arrows). Colocalization was
found in the PLCo, and the posteromedial cortical amygdaloid nuclei (PMCo) (black arrows), and the MePV (black arrowhead). Lower level of β-
gal staining was detected in mature neurons in the anterolateral amygdalohippocampal area (AHiAL) (red arrowhead). Boxed region in (e) is
shown in (f). (f) Higher magnification revealed strong expression of β-gal in mature neurons in the PMCo and sparse expression in mature
neurons in the AHiAL. (g) Colocalization experiment, using an anti-β-gal antibody (green), and an NR2F2 antibody (red), performed on adult brain
cryosections revealed strong β-gal labeling in cells expressing the Nr2f2 mouse gene in brain regions extending from the PMCo (white
arrowhead) to the MePV (white arrow). Lower levels of β-gal were detected in the AHiAL (red arrow). Boxed region in (g) is shown in (h). (h)
Higher magnification revealed strong expression of β-gal (green) in Nr2f2-positive cells (red) in the PMCo (white arrow) and lower expression in
the AHiAL (white arrowhead). LV, lateral ventricle. Scale bar: (a-d) 1 mm; (e,g) 100 μm; (f,h) 20 μm.
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Strong staining was detected in various thalamic nuclei
(Figure 5d). Colocalization experiments on cryosections re-
vealed that the NR2F2-lacZ reporter gene (blue) was
expressed in mature neurons, positive for NeuN (brown),
in all brain regions, including the BLP, and BMP (Figure 5e).
Colocalization was found in the PLCo, PMCo, and MePV
(Figure 5e). Lower levels of NR2F2-lacZ expression were
detected in mature neurons in the anterolateral amygdalo-
hippocampal area (AHiAL), and posteromedial amyg-
dalohippocampal area (AHiPM) (Figure 5e; higher
magnification, Figure 5f). The β-gal-positive cells (blue)
did not colocalize with GFAP (brown), a marker of astro-
cytes (data not shown). An additional colocalization ex-
periment, also performed on adult brain cryosections,
revealed strong β-gal labeling in cells expressing the
Nr2f2 mouse gene in brain regions extending from the
PMCo to the MePV (Figure 5g,h). Lower levels of β-gal
were detected in the AHiAL (Figure 5g,h).Human regulatory regions specifying expression in adult
brain regions of therapeutic interest are functionally
conserved from human to mouse
Initially, in choosing the BACs for each gene in this
study, and again to understand the relevance of the ex-
pression pattern results obtained from the four human-
ized mouse models, we examined the primary literature
and public genomic databases. Specifically, we per-
formed comparative sequence alignment of the BACs
against multiple genomes using the University of Califor-
nia, Santa Cruz (UCSC) genome browser [48]. Further,
we compared our expression results against the data-
bases of the ABA, BGEM, and EGFP-reporter mouse
models generated throughout GENSAT.The AMOTL1-lacZ animals showed staining in the
thalamic nuclei at P7, which correlated with available ex-
pression data from the ABA at similar developing time-
points (P4 and P14). In contrast, the ABA data showed
an absence of expression in the developing HPF for both
timepoints suggesting a discrepancy with expression re-
sults from our human construct. However, the expres-
sion results obtained from the ABA in the adult brain
for the Amotl1 gene did correlate with the results ob-
tained from our human construct, with expression in
the thalamic nuclei, and HPF regions CA1 and CA3.
Thus, the simplest explanation of the developmental dis-
crepancy in expression in the HPF is a sensitivity differ-
ence, with the MaxiPromoter driven lacZ being detected
earlier than the ABA in situ hybridization for endogenous
mouse transcripts. This would presume that both are being
expressed, but that lacZ detection is more sensitive than in
situ hybridization for the endogenous gene. Since, both
studies were performed on the C57BL/6J background;
strain differences are unlikely to be a factor. However, it is
also formally possible that human regulatory regions im-
portant for silencing expression of the AMOTL1 human
gene in the developing HPF are non-functional in mouse,
or that they are missing from the MaxiPromoter construct
(Figure 6a). Regardless, the key regulatory regions allowing
expression of the AMOTL1 gene in the anteromedial, and
anteroventral thalamic nuclei, for which this gene was
chosen, as well as the HPF regions CA1 and CA3 in the
adult brain, are functionally conserved from human to
mouse and were included in our construct.
The MAOA-lacZ animals showed a staining pattern
suggesting expression in the developing LC at P7, which
correlated with available expression data from the ABA
(P4 and P14) and BGEM (P7) at similar developing
timepoints. Staining of adult brain sections in our mouse
Figure 6 Comparative genomics delineated the DNA boundaries that were sufficient for adult brain-specific expression of AMOTL1 and
MAOA. Coordinates corresponding to the human bacterial artificial chromosome (BAC) constructs used in this study were retrieved and
visualized using the University of California Santa Cruz (UCSC) genome browser. (a) DNA alignment of the human AMOTL1 BAC (RP11-936P10)
with the mouse genome delineated the genomic DNA boundaries sufficient for proper expression of this human gene in the anterior thalamic
nuclei in both developing (P7) and adult mouse brain, regions for which this gene was chosen. (b) DNA alignment of the human MAOA BAC
(RP11-475M12) with the mouse genome delineated the genomic DNA boundaries sufficient for proper expression of this human gene in the
locus coeruleus (LC) in both developing (P7) and adult mouse brain, regions for which this gene was chosen. One hypothesis suggested by our
results was that additional conserved regulatory elements in the 3′ coding and non-coding regions (red rectangle) could be important in
narrowing the brain expression of this human gene.
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which again correlated with the ABA. Colocalization ex-
periments revealed that the MAOA-lacZ reporter gene
was expressed in TH-positive neurons in the LC, which
correlated with previously observed results for the
mouse gene [21]. Additional staining was detected in the
lateral cerebellar nuclei as well as the medial and lateral
vestibular nuclei. A careful review of the results obtained
by in situ hybridization from the ABA revealed low level
of expression in the lateral cerebellar nuclei, and absence
of expression in the medial and lateral vestibular nuclei.
Again, the discrepancies between our results and the ones
obtained from the ABA could be attributable to sensitivity
differences; with the MaxiPromoter-driven lacZ being
more easily detected than the ABA in situ hybridizationfor endogenous mouse transcripts. Another possible ex-
planation is that human negative regulatory elements
within the BAC are non-functional in mouse. However, in
this case we note that the BAC used in the current study
was chosen to favor the inclusion of predicted regulatory
regions 5′ of the gene, but because of the size of MAOA
and the available BACs, lacked extensive 3′ coding and
non-coding sequences (Figure 6b, red rectangular box).
Subsequent to obtaining these expression results, com-
parative genomic investigation using the UCSC genome
browser and focused on the 3′ untranslated region (UTR)
of human MAOA revealed the presence of a microRNA
binding site for a human-mouse conserved microRNA
(miR-495, chrX:43606034–43606041). MicroRNAs have
been implicated in various biological processes, including
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cluding the MAOA 3′ UTR region in future gene expres-
sion studies [49-53]. Nevertheless, the expression results
in TH-positive neurons in the LC in the adult brain
showed that the regulatory regions allowing expression of
the MAOA gene in these cells, for which this gene was
chosen, are functionally conserved from human to mouse,
and were included in our construct (Figure 6b).
The NOV-lacZ animals showed staining in the devel-
oping RM, and light staining in the HPF at P7, which
correlated with available expression data from the ABA
(P4 and P14), BGEM (P7), and GENSAT (P7). However,
the NOV-lacZ animals at P7 had no detectable expres-
sion in developing cortical layers, which was seen at
similar timepoints in ABA, BGEM, and GENSAT.
Nevertheless, by adulthood the NOV-lacZ animals dem-
onstrated strong expression in mid-cortical layers, as
well as the HPF, and BLP, results that correlated with
those obtained for the ABA, BGEM, and GENSAT data-
sets. Given the small size of the NOV gene, the proxim-
ity of neighboring genes, and substantial 5′ and 3′
sequences in the BAC chosen (Figure 7a), the simplest
explanation for the temporal delay in expression of our
reporter gene in the cortical layers would be a lack of
function of human regulatory sequences in mouse, al-
though it is also formally possible that the MaxiPromo-
ter construct is missing regulatory sequences. Building
on this latter hypothesis, sequence alignment between
the BAC construct used in our study and the one used
by GENSAT suggested that the additional regulatory re-
gions may be present in human-DNA homologous to
the large non-overlapping 3′ mouse-BAC region. Finally,
additional detailed expression analyses revealed staining
of the NOV-lacZ reporter gene in layers II, IV and VI of
the cortex, results that correlated with expression data
coming from both the ABA, and GENSAT. Expression
in the HPF was detected in CA1 pyramidal neurons in
our NOV mouse model, results that again correlated
with the mouse model generated by GENSAT. This sug-
gests that the regulatory regions allowing expression of
the NOV gene in the adult BLP, the brain region for
which this gene was chosen, as well as the cortical layers
and HPF, are functionally conserved from human to
mouse, and were included in our construct (Figure 7a).
The NR2F2-lacZ animals showed staining in the devel-
oping amygdala, and subthalamic nuclei at P7, which cor-
related with available expression data from BGEM and
GENSAT at the same timepoint. However, NR2F2-lacZ
animals at P7 had no detectable expression in the develop-
ing hypothalamus, which was seen at similar timepoints in
BGEM, and GENSAT. Nevertheless, by adulthood the
NR2F2-lacZ animals demonstrated expression in the an-
terior hypothalamic nuclei, as well as the basomedial
amygdalar nuclei, results that correlated with thoseobtained for the ABA, and GENSAT datasets. Again, this
temporal delay in expression of our reporter gene in the
hypothalamus may be due to lack of function of human
regulatory sequences in mouse, or that they are missing
from the MaxiPromoters construct.
For NR2F2, additional detailed expression analyses in-
cluded colocalization experiments performed using an
antibody for β-gal and an anti-NR2F2 antibody; the lat-
ter was raised against the human protein but cross
reacted with the mouse ortholog. This analysis revealed
specific expression of the NR2F2-lacZ reporter con-
struct in cells expressing the Nr2f2 endogenous mouse
gene in various amygdala regions. We obtained similar
detection levels when comparing the β-gal staining to
the endogenous Nr2f2 mouse gene in regions extend-
ing from the PMCo to the MePV in the amygdala.
Interestingly, our NR2F2-lacZ reporter strain gave lower
detection levels in the AHiAL, an amygdala region that
showed robust detection levels of the endogenous Nr2f2
mouse protein (Figure 5g,h). This discrepancy could again
result from a lack of function of human regulatory se-
quences in mouse, or the absence of regions that regulate
expression level in the AHiAL in our MaxiPromoter con-
struct. Finally, characterization using the NR2F2 antibody
revealed Nr2f2 protein in retinal amacrine cells [8]. How-
ever, the NR2F2-lacZ reporter strain demonstrated no ex-
pression in the retina (data not shown). In contrast, the
GENSAT project reported expression of their Nr2f2-
EGFP reporter strain in retinal amacrine cells (Figure 7b)
[54]. Thus, we observed a discrepancy between the results
obtained using our reporter mouse model and those from
both the endogenous Nr2f2 mouse gene, and the mouse
model generated by GENSAT. One possible explanation
was eliminated when sequence alignment of NR2F2 human
gene revealed that the AUG we targeted with our reporter
is for the same NR2F2 isoform recognized by the NR2F2
antibody as mapped by previous studies (Figure 7c) [8,10].
Thus, the lack of expression of our construct in retinal
amacrine cells is attributable to the lack of function of hu-
man regulatory sequences in mouse, or the absence of
those regulatory regions in the MaxiPromoter construct. If
the latter is the case, we can hypothesize that these regula-
tory regions may be present in human-DNA regions hom-
ologous to the additional 5′ non-overlapping portion of
the mouse-BAC construct used in the GENSAT project
(Figure 7b). Nevertheless, the expression results in amyg-
dala in the adult brain showed that the regulatory regions
allowing expression of the NR2F2 gene in this region, for
which this gene was chosen, are functionally conserved
from human to mouse, and were included in our construct.
Despite the minor discrepancies between the expres-
sion results of our four different MaxiPromoter con-
structs and the corresponding expression from the
endogenous mouse gene, it is noteworthy that by using
Figure 7 (See legend on next page.)
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Figure 7 Comparative genomics delineated the DNA boundaries that were sufficient for adult brain-specific expression of NOV
and NR2F2. Coordinates corresponding to the human bacterial artificial chromosome (BAC) constructs used in this study were retrieved
and visualized using the University of California Santa Cruz (UCSC) genome browser. (a) DNA alignment of the human NOV BAC (RP11-
840I14) (black), against both the RP23-235B13 BAC construct used in the Gene Expression Nervous System Atlas (GENSAT) mouse model
(blue), and the mouse genome, delineated the genomic DNA boundaries sufficient for proper expression of this human gene in the
basolateral amygdaloid nuclei, cortical layers, and pyramidal neurons in the cornu ammonis 1 (CA1) regions in the adult brain. One
hypothesis suggested by our results was that additional functionally conserved regulatory elements homologous to the large non-
overlapping 3′ mouse-BAC region are necessary for proper human-gene expression in the developing cortical layers at P7. (b) DNA
alignment of the human NR2F2 BAC (RP11-134D15) (black), against both the RP23-109L9 BAC construct used in the GENSAT mouse model
(blue) and the mouse genome, delineated the genomic DNA boundaries sufficient for region-specific expression of this human gene in
the basolateral, and corticolateral amygdaloid nuclei in the adult brain. One hypothesis suggested by our results was that additional
functionally-conserved regulatory elements homologous to the non-overlapping 5′ mouse-BAC region are necessary for proper expression
in the developing hypothalamus at P7. Black rectangle box in (b) is shown in (c). (c) Sequence alignment using the coordinates of the
primers used in the BAC lacZ retrofitting process (grey bars) and the cDNA sequence used to generate an anti-NR2F2 antibody (black bar),
suggested that the absence of expression of the NR2F2-lacZ constructs in retinal amacrine cells was not attributable to detection of
different isoforms of NR2F2.
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case to delineate the genomic DNA boundaries that
were sufficient for expression in the specifically chosen
adult brain regions. The delineation of these genomic
DNA boundaries is not only important as a proof of
principle, but is also crucial for the design of future
MiniPromoter constructs for gene-based delivery to
these therapeutically important regions.Conclusions
Here, we describe an in vivo approach by which to fur-
ther refine our understanding of gene-expression regula-
tion. We first generated a list of ten human genes with
expression enriched in brain regions of therapeutic inter-
est, and predicted to have all essential non-coding regu-
latory regions contained within an identified BAC. We
then tested the veracity of these predictions using novel
knock-in reporter mouse models. This approach, using
the HuGX method, was built on expertise from five spe-
cialized laboratories, and scaled to higher-throughput
with the help of the pipeline previously designed within
the Pleiades Promoter Project [5,7].
For the ten genes chosen, BACs were recovered for
nine, and of these BACs eight were fully retrofitted to
contain the Hprt homology arms and a reporter gene
(lacZ or EGFP). The success rate of 89% (8 out of 9) in
the retrofitting steps demonstrates the efficiency of the
approach. The success of obtaining correctly targeted
ESC clones for all constructs (8/8), at a rate that varied
between 20 and 50%, with an average of 35%, was very
efficient. The high correct-targeting rate, afforded high
selectivity with regard to the ESC clones injected and in-
creased efficiency of obtaining germline transmission,
further streamlining the method. Finally, we observed
expression from the human gene in mouse for 63% (5/8)
genes. Two of the negative results have enabled testablehypotheses to be developed identifying additional critical
regulatory regions for those genes.
Four of the five positive mouse strains, including
AMOTL1-lacZ, MAOA-lacZ, NOV-lacZ, and NR2F2-lacZ
were characterized in this study. The fifth construct,
NR2E1-lacZ, was the subject of extensive characterization
published [45]. For all the positive strains, the expression
for the human gene matched the predicted specific adult
brain region for which they were chosen. This defined the
genomic DNA boundaries that were sufficient for adult
brain-specific expression, as well as refined our knowledge
regarding the complexity of gene regulation, and demon-
strated that a careful investigation, using both elements
from publicly available resources and bioinformatics, can
lead to accurate prediction of gene expression.
Careful analyses of the expression patterns of these
human genes demonstrated slight variations from avail-
able mouse expression data. These variations could be a
true reflection of species-specific differences in expres-
sion. However, they could result from the misuse of
human regulatory regions in the mouse environment, or
the omission of minor regulatory regions from the BAC
construct. Another possible source of difference lies in the
effects resulting from the insertion site on the X chromo-
some. The endogenous Hprt locus is widely expressed
[40,41], nevertheless, it is considered a relatively neutral
docking site since the expected restricted expression is ob-
served from tissue-specific promoters inserted at the locus
[5,55-60]. In addition, it has been suggested that the intro-
duction of a larger DNA construct (that is, BAC DNA)
would further minimize the risk of influences from the
Hprt insertion site by providing the essential chromatin
environment, thus producing endogenous patterns of gene
regulation [61]. Nevertheless, the possibility remains that
the slight variation in expression between our knock-in
human construct and the mouse gene could be attribut-
able to influence from the Hprt locus.
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ment of small human promoters to finely regulate the ex-
pression of therapeutic genes in a cell-specific manner.
The results from this project delineate, refine, and cha-
racterize non-coding-regulatory regions of human genes.
Thus, we have characterized the expression pattern, and
the non-coding regulatory regions, of four therapeutically
important human brain genes. In the near future, refined
mouse models using subsets of the regulatory regions de-
fined within these boundaries could lead to the generation
of MiniPromoters driving the expression of a gene therapy
specifically in the thalamus, locus coeruleus, and various
amygdala nuclei in the brain.
Methods
MaxiPromoter design
The BAC constructs came from the RPCI-11 human male
BAC library [62] accessed 4 January 2012 (BAC numbers,
see Table 1). Suitable BACs were selected based on cover-
age of the gene of interest and its upstream sequence.
Candidate regulatory regions were predicted based on se-
quence conservation and experimental data provided in
the UCSC genome browser, and a manual review of the
scientific literature. Under the criteria applied, the ideal
BAC would cover the entire gene up to, but not including,
the promoter regions of neighboring genes. If multiple
BACs were available, priority was given to the one that in-
cluded the most upstream sequence. Two 50 bp oligo-
nucleotide recombination arms were designed for the
insertion of the reporter gene in the BAC. The left arm
targeted immediately upstream of the endogenous ATG.
Ideally, the right arm targeted immediately after the
end of the same exon. Because of sequence composition
challenges for retrofitting, in some cases the initial right
arm oligonucleotide designs were altered to target further
downstream.
BAC retrofitting
BACs were modified by two sequential steps of retrofit-
ting using the lambda recombination system [63]. The
first retrofitting step allowed the insertion of Hprt hom-
ologous recombination targeting arms as we have de-
scribed previously [45]. The second step allowed the
insertion of a reporter cassette (lacZ or EGFP) at the
ATG of the specified gene. Only the lacZ or EGFP cod-
ing sequence, including a STOP codon, was added at the
ATG. No intron or polyA signal was added, as the en-
dogenous splicing and polyA were to be used to best re-
flect the natural gene expression. The specific primers
used for the retrofitting of each construct are listed in
Table 4. The retrofitting of the reporter cassette was per-
formed as we have described previously [45]. Briefly, the
reporter cassette was designed to contain a kanamycin
gene, allowing the selection of correctly retrofitted clones.This resistance gene was designed with flanking full frt
sites [64], which were used to excise the kanamycin gene
via induction of FLPe recombinase [65,66]. All newly cre-
ated DNA junctions, whether for Hprt arms or the re-
porter cassette, were sequence verified. The resulting
MaxiPromoter constructs contained a reporter gene under
the influence of the human regulatory regions of the speci-
fied gene (for a complete list of genes, see Table 1).
Mouse strain generation, husbandry, and breeding
The strains were generated using a variation of the pre-
viously described strategy to insert constructs 5′ of Hprt
on the mouse X chromosome (HuGX) [7,46,61,67].
Briefly, BAC DNA was purified using the Nucleobond
BAC 100 kit (Clontech Laboratories, Mountain View, CA,
USA) and linearized with I-SceI. The BAC constructs were
electroporated into ESCs using the following conditions:
voltage, 190 V; capacitance, 500 μF; resistance, none; using
a BTX ECM 630 Electro cell manipulator (BTX, San
Diego, CA, USA) [45]. ESC clones were selected in hypo-
xanthine aminopterin thymidine (HAT) media, isolated,
and DNA purified. Human-specific PCR assays were de-
signed to be on average 8 kb apart (range 0.334 to 20)
throughout the BAC construct, and used to screen the
ESC clones as well as verify the integrity of the BAC
inserted into the mouse genome [45,46]. Table 2 lists all
the ESC lines used and their associated genotype. ESC der-
ivation and culture was conducted as we have described
previously [46]. Correctly targeted ESC clones were micro-
injected into B6(Cg)-Tyrc-2J/J (B6-Alb) (JAX Stock#000058)
blastocysts to generate chimeras that were subsequently
bred to B6-Alb females to obtain female germline offspring
carrying the BAC insert. The female germline offspring
were then bred to C57BL/6J (B6) (JAX Stock#000664)
males and backcrossing to B6 continued such that mice
used in this study were N3 or higher. Table 3 list the
details about the strains used in this study, these are avail-
able at The Mutant Mouse Regional Resource Center
(MMRRC) [68]. Male animals were used in all studies to
avoid any variability due to random X-inactivation of the
knock-in alleles at Hprt, and the age of the adult animals
used in this study ranged from P51 to P305.
For the cre/loxP experiment, the ACTB-cre allele was
obtained from strain FVB/N-Tg(ACTB-cre)2Mrt/J (JAX
Stock#003376) and then backcrossed to B6 such that mice
used in the study were N10 or higher. Females, heterozy-
gous for the human BAC MaxiPromoter reporter genes
(Hprttm66(Ple5-lacZ)Ems/+, Hprttm68(Ple127-lacZ)Ems/+, Hprttm69
(Ple134-lacZ)Ems/+, Hprttm75(Ple143-lacZ)Ems/+) were bred to
males heterozygous for the ACTB-cre gene (ACTB-cre/+).
The resulting offspring contained experimental males,
hemizygous for the reporter genes, and heterozygous for
the ACTB-cre gene (Hprttm66(Ple5-lacZ)Ems/Y, ACTB-cre/+;
Hprttm68(Ple127-lacZ)Ems/Y, ACTB-cre/+; Hprttm69(Ple134-lacZ)
Table 4 Primers used for reporter-gene retrofitting
Gene Primers (5′-3′) Sequencea
AMOTL1 Forward CCGGCAGCCGTCTTCCCCAGCCGAGGGACTGAACTAGCCATGATCGCCTCatggcggatcccgtcgtttt
Reverse GTGGGAGACTCGGAGACGCCCTCCCGGCACCTCGAGTGGGGGCTGGTTACgaagttcctatactttctag
LCT Forward TTGCAGTTATAAAGTAAGGGTTCCACATACCTCCTAACAGTTCCTAGAAAatggtgagcaagggcgagga
Reverse TGTGTGATGAAGGTTGCCGAGGGGTCACCATCAGGTCAATGTGTACTCACgaagttcctatactttctag
MAOA Forward TTGCCGTCCCCACTCCTGTGCCTACGACCCAGGAGCGTGTCAGCCAAAGCatggcggatcccgtcgtttt
Reverse ACCCCTCACTGGCCAGGGTCCCCCAGGCCACCGCTACGGTCCACACTGACgaagttcctatactttctag
NGFR Forward CCGCAAAGCGGACCGAGCTGGAAGTCGAGCGCTGCCGCGGGAGGCGGGCGatggcggatcccgtcgtttt
Reverse GGAGTTCTGATCCCGGGAAAGGGAGCGGGCCCCCTCCGGCTAACACTCACgaagttcctatactttctag
NOV Forward TACAGCGAAGAAAGTCTCGTTTGGTAAAAGCGAGAGGGGAAAGCCTGAGCatggcggatcccgtcgtttt
Reverse ACCAAGGCGGGCAAAGTAACTTGGGGGCATCTTAAGGGTGTGCCACTTACgaagttcctatactttctag
NR2E1 Forward GCCGGGACTCGGGCAGCGCCCACCAACCGCTCCGCCCCGGGACAGCCAGCatggcggatcccgtcgtttt
Reverse TCGCCCCAGGCTGCGCGCCTAGGCCCCACGGCGGCCCGAGAGGTACCCACgaagttcctatactttctag
NR2F2 Forward CGCCGCCCGCAGCCAGGGGAGCAGGAAGTCCGGACGCAGCCCCCATAGATatggcggatcccgtcgtttt
Reverse CCAGGACCCCGGGACCCAGGACGAGGGAAGGAGAAATGAGAGGCCGATACgaagttcctatactttctag
PITX2 Forward CCGCCGCTTCTTACAGCCTTCCTTCTCTTCTGTTTTGCAGATAACGGGGAatggcggatcccgtcgtttt
Reverse GTGGCGCGGCCTCCCGTCCGATGACCCGGGCAGGAGAAGGGGGTTCTTACgaagttcctatactttctag
aCapital letters, sequence matching the mouse genome; lowercase letters, sequence matching the reporter gene (forward primer) or the kanamycin cassette
(reverse primer).
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and control males, hemizygous for the MaxiPromoter re-
porter genes only (Hprttm66(Ple5-lacZ)Ems/Y, +/+; Hprttm68
(Ple127-lacZ)Ems/Y, +/+; Hprttm69(Ple134-lacZ)Ems/Y, +/+;
Hprttm75(Ple143-lacZ)Ems/Y, +/+). Animals of the appropriate
genotype were kept and processed for lacZ staining as de-
scribed below.
All mice were maintained in the pathogen-free Centre
for Molecular Medicine and Therapeutics animal facility
on a 7 AM to 8 PM light cycle, 20 ± 2°C with 50 ± 5%
relative humidity, and had food and water ad libitum.
All procedures involving animals were in accordance
with the Canadian Council on Animal Care (CCAC) and
UBC Animal Care Committee (ACC) (Protocol# A09-
0980 and A09-0981).
Embryo and adult tissue preparation
Time-pregnant mice were killed by cervical dislocation
and embryos at E12.5 were dissected, and then fixed in 4%
paraformaldehyde (PFA) with 0.1 M PO (0.1M Na2HPO4)
buffer (pH 7.2 to 7.4) for 4 h at 4°C. Whole embryos were
incubated in lacZ staining solution (X-gal (1 mg/ml),
MgCl2 (2 mM), K3Fe(CN)6 (4 mM), K4Fe(CN)6 (4 mM) in
1 × phosphate-buffered saline (PBS)) overnight at 37°C
and were subsequently washed in three volumes of 1 ×
PBS before being photographed. Embryos having the de-
sired genotype were cleared as described in the literature
[69] and pictures were taken in 100% glycerol solution.
Intracardial perfusions were performed on avertin-
anesthetized mice with 4% PFA with 0.1 M PO buffer(pH 7.2 to 7.4). Brain tissues destined to be 1 mm sec-
tioned were collected and post fixed in 4% PFA for an
additional 2 h at 4°C before being sectioned in a rodent
brain matrix (RBM-2000S/RBM-2000C, ASI Instruments,
Michigan, USA). The sectioned brains were incubated in
lacZ staining solution for a duration varying between 2 h
to overnight at 37°C and were washed in 1 × PBS before
being photographed. Brain tissues destined to be cryosec-
tioned were directly transferred to 20% sucrose with
0.05 M PO buffer overnight at 4°C and embedded the next
day in optimal-cutting-temperature (OCT) compound
(Tissue-tek, Torrance, CA, USA) on dry ice. Eye tissues
destined to be cryosectioned were incubated in lacZ stain-
ing solution overnight at 37°C and were washed in 1 ×
PBS before being post fixed for 2 h in 4% PFA at 4°C. The
eyes were washed in 1 × PBS, then transferred to 20% su-
crose with 0.05 M PO buffer overnight at 4°C and embed-
ded the next day in OCT on dry ice.
Histology
Brain structures were identified using The Mouse Brain
in Stereotaxic Coordinates, third edition [70].
For immunofluorescence, 25 μm cryosections from
adult brains (floating sections) were rehydrated in se-
quential washes of PBS, permeabilized in PBS with 0.1%
triton, and quenched in 0.1 M glycine-PBS solution.
The cryosections were blocked with 1% BSA in PBS
with 0.1% triton for 1 h at room temperature before
applying the primary antibodies. Colocalization exp-
eriments were performed using chicken anti-β-gal
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1:5,000, mouse anti-NR2F2 antibody (R&D systems,
Minneapolis, MN, USA; PP-H7147-00) 1:100, and incu-
bated overnight at 4°C. Corresponding secondary anti-
bodies coupled to Alexa 488 or Alexa 594 (Invitrogen,
Burlington, Ontario, Canada) were incubated at room
temperature for 2 h in the dark (1:1,000). Hoechst
33342 was used for nuclear staining on all immuno-
fluorescence sections.
For immunohistochemistry staining of adult brain,
25 μm cryosections (floating sections) were rehydrated in
sequential washes of PBS, permeabilized in PBS with 0.1%
triton before being incubated in lacZ solution overnight at
37°C. The following day, the sections were rinsed, post
fixed in 2% PFA for 10 minutes, and blocked with 0.3%
bovine serum albumin (BSA), 10% normal goat serum so-
lution for 20 minutes. Primary antibodies were incubated
overnight at 4°C using the following dilutions: rabbit anti-
TH antibody (Pel-freez Biologicals, Rogers, AR, USA;
P40101-0) (1:500), mouse anti-NeuN (Millipore, Billerica,
MA, USA; MAB377) (1:500), mouse anti-GFAP (New
England BioLabs, Cell Signaling Technology, Danvers,
MA, USA; mAB3670) (1:200), rabbit anti-Brn3 (recogniz-
ing Brn3a, Brn3b, Brn3c, also known as Pou4f1, Pou4f2,
Pou4f3) (Santa Cruz, Dallas, TX, USA; sc-28595) (1:1,000),
rabbit anti-calbindin (Abcam, San Francisco, CA, USA;
ab49899) (1:1,000). The third day, sections were rinsed and
corresponding secondary antibody coupled to biotin (Vec-
tor Laboratories, Burlingame, CA, USA) were incubated at
room temperature for 1 h (1:200). The sections were finally
processed for standard avidin-biotin immunocytochemical
reactions using the ABC kit from Vector Laboratories.
Immunolabeling was visualized using 3.3-diaminobenzi-
dine tetrahydrochloride (DAB) (Roche, St Louis, MO,
USA). Sections were dehydrated in subsequent washes of
50%, 70%, 95%, 100% ethanol, and xylene before being
mounted for microscopy.
For adult eyes, stained with lacZ, 20 μm cryosections
were mounted directly on slides and pressed for 30 mi-
nutes before being processed for counterstaining or
antibody labeling. Antibody staining was performed as
previously described for floating brain sections. Counter-
staining was performed using neutral red as follows: slides
were washed once in PBS for 2 minutes, followed by a 2-
minute wash in water. They were then incubated for 45 s
in neutral red solution before being subsequently dehy-
drated in 70% to 100% ethanol and xylene and then
mounted for microscopy.
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